AI Science Tracker

Iterative machine learning identifies potent inhibitors of alpha-synuclein secondary nucleation

University of Cambridge; US National Institutes of Health, National Institute of Allergy and Infectious Diseases; A*STAR; Indiana University School of Medicine · 17 Apr 2024 · chemistry

Discovery

Iterative machine learning identifies potent inhibitors of alpha-synuclein secondary nucleation

A structure-based iterative-learning workflow combined prior α-synuclein fibril-binding hits, a junction-tree variational autoencoder, a random-forest regressor and Gaussian-process residual model to rank compounds for repeated testing. Prospective iterations produced multiple molecules inhibiting seeded α-synuclein aggregation in vitro; lead I4.05 had a reported kinetic inhibitory constant (KIC50) of 0.52 μM (95% CI 0.45–0.59 μM), compared with extrapolated values of 18.2 μM for its parent and 36.4 μM for Anle-138b in the authors’ assay. Leads also showed activity in lipid-induced and spontaneous aggregation assays.

Technology: Iterative structure-based learning workflow using a junction-tree variational autoencoder, random-forest regressor and Gaussian-process residual model

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: A structure-based iterative-learning workflow combined prior α-synuclein fibril-binding hits, a junction-tree variational autoencoder, a random-forest regressor and Gaussian-process residual model to rank compounds for repeated testing.
  • Still unknown: Evidence is biochemical/in-vitro inhibition of α-synuclein aggregation, including seeded, lipid-induced and spontaneous assays. The paper does not establish animal efficacy, neuronal protection or clinical benefit. The KIC50 and comparison values are assay-specific; no random-molecule comparator was tested, and model QSAR R² was described as modest. This is related to, but not the same paper/result as, the earlier docking-screen study that supplied starting compounds.
  • AI role: The machine-learning model ranked a ZINC-derived evaluation set for potency using earlier assay measurements, then researchers tested and fed results from successive rounds back into the model. It proposed compounds for experimental testing; aggregation assays measured outcomes. Initial fibril binders came from an earlier docking-and-screening study, so this paper reports iterative optimization rather than an entirely independent start.

Evidence sources: https://www.nature.com/articles/s41589-024-01580-x.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 60 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.